Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Living Cell Technologies ( (AU:1AI) ) just unveiled an announcement.
Algorae Pharmaceuticals has notified the market of the issue of 30 million unquoted options, each exercisable at $0.014 and expiring on 1 December 2029. The options, recorded under ASX security code 1AIAT, form part of a previously announced transaction and will not be quoted on the ASX, indicating a targeted use in financing or incentive arrangements that could affect future capital structure.
The issuance, effective from 13 March 2026, underscores the company’s ongoing reliance on option-based securities to support its strategic and operational objectives. While the options are unquoted, their scale and long-dated nature are relevant for existing stakeholders monitoring potential dilution and the company’s longer-term funding flexibility.
The most recent analyst rating on (AU:1AI) stock is a Hold with a A$0.02 price target. To see the full list of analyst forecasts on Living Cell Technologies stock, see the AU:1AI Stock Forecast page.
More about Living Cell Technologies
Algorae Pharmaceuticals Limited operates in the pharmaceuticals sector, focusing on drug development and related biotechnology activities. The company is listed on the ASX under issuer code 1AI and utilizes various equity instruments, including unquoted options, as part of its capital management and incentive structures.
Average Trading Volume: 1,468,688
Technical Sentiment Signal: Hold
Current Market Cap: A$23.98M
See more data about 1AI stock on TipRanks’ Stock Analysis page.